Loading data for SPRY — first visit, this takes a few seconds.
ARS Pharmaceuticals Inc. (SPRY)
NasdaqGM: SPRY
· Real-Time Price · USD
6.38
+0.08 (1.27%)
At close: Aug 19, 2026, 5:58 PM
ARS Pharmaceuticals Inc. (SPRY) Stock Price, Analysis & Data
1.27% (1D)
No data available
| Bid | 3.89 |
| Market Cap | 634.47M |
| Revenue (ttm) | 116.93M |
| Net Income (ttm) | -215.43M |
| Beta | 0.97 |
| EPS (ttm) | -2.18 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.17 |
| P/B (ttm) | 10.34 |
| P/S (ttm) | 5.43 |
| Earnings Date | Nov 10, 2026 |
| Ask | 6.72 |
| Volume | 543,551 |
| Avg. Volume (20D) | 2,061,861 |
| Open | 6.42 |
| Previous Close | 6.30 |
| Day's Range | 6.35 - 6.58 |
| 52-Week Range | 4.91 - 15.09 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About SPRY
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California....
Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 195
Stock Exchange NasdaqGM
Ticker Symbol SPRY
Website https://ars-pharma.com
Financial Performance
In 2025, ARS Pharmaceuticals's revenue was 84.28M, a decrease of -5.46% compared to the previous year's 89.15M. Earnings were -171.3M, a decrease of -2,241.76%.
Financial StatementsEarnings Surprise
ARS Pharmaceuticals has released their quarterly earnings on Aug 13, 2026:
ARS Pharmaceuticals Inc. is scheduled to release its earnings on Nov 10, 2026, during market hours.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2